Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

Lilly

Status and phase

Completed

Phase 2

Conditions

Social Phobia

Treatments

Drug: paroxetine

Drug: placebo

Drug: LY686017

Study type

Interventional

Funder types

Industry

Identifiers

7958

H8R-MC-HJAG

Details and patient eligibility

About

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female outpatients at least 18 years of age and not more than 65 years of age.
Must sign the informed consent document.
Present at Visit 1 with social anxiety disorder based on a Clinical Global Impression-Severity score of greater than or equal to 4.
Females of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control.
Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol.

Exclusion criteria

Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, post-traumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months.
Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders.
Have the presence of an Axis II disorder, except avoidant personality disorder.
Have a serious medical illness.
Have abnormal thyroid-stimulating hormone (TSH) concentrations or are taking thyroid supplements.